RU2005101202A - Производные тиазола в качестве ингибиторов фосфодиэстераза iv - Google Patents
Производные тиазола в качестве ингибиторов фосфодиэстераза iv Download PDFInfo
- Publication number
- RU2005101202A RU2005101202A RU2005101202/04A RU2005101202A RU2005101202A RU 2005101202 A RU2005101202 A RU 2005101202A RU 2005101202/04 A RU2005101202/04 A RU 2005101202/04A RU 2005101202 A RU2005101202 A RU 2005101202A RU 2005101202 A RU2005101202 A RU 2005101202A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- asthma
- group
- accordance
- methoxyphenyl
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims 2
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- -1 heterocyclic radical Chemical class 0.000 claims 34
- 125000004432 carbon atom Chemical group C* 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 29
- 208000006673 asthma Diseases 0.000 claims 24
- 239000012453 solvate Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 230000008506 pathogenesis Effects 0.000 claims 16
- 206010006451 bronchitis Diseases 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 206010006895 Cachexia Diseases 0.000 claims 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000024780 Urticaria Diseases 0.000 claims 9
- 206010046851 Uveitis Diseases 0.000 claims 9
- 201000009267 bronchiectasis Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 208000027866 inflammatory disease Diseases 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000001544 thienyl group Chemical group 0.000 claims 7
- 206010017533 Fungal infection Diseases 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 5
- 206010010741 Conjunctivitis Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 206010040070 Septic Shock Diseases 0.000 claims 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 5
- 201000008937 atopic dermatitis Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 206010035653 pneumoconiosis Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 201000009890 sinusitis Diseases 0.000 claims 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 4
- YKYIFUROKBDHCY-ONEGZZNKSA-N (e)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one Chemical group CCO\C=C\C(=O)C(F)(F)F YKYIFUROKBDHCY-ONEGZZNKSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 208000031888 Mycoses Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims 4
- 125000003971 isoxazolinyl group Chemical group 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 125000005968 oxazolinyl group Chemical group 0.000 claims 4
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000002769 thiazolinyl group Chemical group 0.000 claims 4
- 125000004306 triazinyl group Chemical group 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 241000721454 Pemphigus Species 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 208000007451 chronic bronchitis Diseases 0.000 claims 3
- 206010009887 colitis Diseases 0.000 claims 3
- 210000003979 eosinophil Anatomy 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 3
- 201000010659 intrinsic asthma Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010014950 Eosinophilia Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 239000000428 dust Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000002427 irreversible effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000009772 tissue formation Effects 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims 1
- PAQSSSAMOJGLGR-UHFFFAOYSA-N 2-[[4-[5-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]-4-methyl-1,3-thiazol-2-yl]phenyl]hydrazinylidene]propanedinitrile Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2C=CC(NN=C(C#N)C#N)=CC=2)C)=C1 PAQSSSAMOJGLGR-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010001076 Acute sinusitis Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 229930183010 Amphotericin Natural products 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 206010003487 Aspergilloma Diseases 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004265 Benign familial pemphigus Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 208000007596 Byssinosis Diseases 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000031973 Conjunctivitis infective Diseases 0.000 claims 1
- 229920000742 Cotton Polymers 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010015287 Erythropenia Diseases 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 206010051011 Fibrinous bronchitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 108010044467 Isoenzymes Proteins 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010025102 Lung infiltration Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010027236 Meningitis fungal Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- IMDYYVIDEIZTSQ-UHFFFAOYSA-N N-[4-[5-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3H-pyridazine-2-carbonyl]-4-methyl-1,3-thiazol-2-yl]anilino]-2H-tetrazole-5-carboximidoyl cyanide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2C=CC(NN=C(C#N)C=3NN=NN=3)=CC=2)C)=C1 IMDYYVIDEIZTSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010063669 Photoelectric conjunctivitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000010443 Steatitis Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 241000272534 Struthio camelus Species 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000028484 Urethral disease Diseases 0.000 claims 1
- 206010046740 Urticaria cholinergic Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 206010046742 Urticaria contact Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- TYTQBFNQOWXLLN-UHFFFAOYSA-N [6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyrazin-2-yl-1,3-thiazol-5-yl)methanone Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2N=CC=NC=2)C)C=C1OC1CCCC1 TYTQBFNQOWXLLN-UHFFFAOYSA-N 0.000 claims 1
- WLQKCGPZYVCEOJ-UHFFFAOYSA-N [6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyridin-2-yl-1,3-thiazol-5-yl)methanone Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2N=CC=CC=2)C)C=C1OC1CCCC1 WLQKCGPZYVCEOJ-UHFFFAOYSA-N 0.000 claims 1
- AKKYFJAOZKZLJU-UHFFFAOYSA-N [6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)methanone Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2C=NC=CC=2)C)C=C1OC1CCCC1 AKKYFJAOZKZLJU-UHFFFAOYSA-N 0.000 claims 1
- JUBJEHDSCFNXQS-UHFFFAOYSA-N [6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-thiophen-2-yl-1,3-thiazol-5-yl)methanone Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2SC=CC=2)C)C=C1OC1CCCC1 JUBJEHDSCFNXQS-UHFFFAOYSA-N 0.000 claims 1
- BMXOQGODFNROHX-UHFFFAOYSA-N [6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-phenyl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2C=CC=CC=2)C)=C1 BMXOQGODFNROHX-UHFFFAOYSA-N 0.000 claims 1
- IHQYWZCCYOZCQE-UHFFFAOYSA-N [6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyrazin-2-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2N=CC=NC=2)C)=C1 IHQYWZCCYOZCQE-UHFFFAOYSA-N 0.000 claims 1
- KSSRXDZTCXRDPZ-UHFFFAOYSA-N [6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyridin-2-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2N=CC=CC=2)C)=C1 KSSRXDZTCXRDPZ-UHFFFAOYSA-N 0.000 claims 1
- XOCYDMINFXPPAL-UHFFFAOYSA-N [6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2C=NC=CC=2)C)=C1 XOCYDMINFXPPAL-UHFFFAOYSA-N 0.000 claims 1
- GNIXMRCOBKNZPG-UHFFFAOYSA-N [6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-thiophen-2-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C2=C(N=C(S2)C=2SC=CC=2)C)=C1 GNIXMRCOBKNZPG-UHFFFAOYSA-N 0.000 claims 1
- IDMCLKSFSKLNTK-UHFFFAOYSA-N [6-(4-methoxy-3-propan-2-yloxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyrazin-2-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C1=NN(C(=O)C2=C(N=C(S2)C=2N=CC=NC=2)C)CCC1 IDMCLKSFSKLNTK-UHFFFAOYSA-N 0.000 claims 1
- RJBNASUMBSVTNZ-UHFFFAOYSA-N [6-(4-methoxy-3-propan-2-yloxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyridin-2-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C1=NN(C(=O)C2=C(N=C(S2)C=2N=CC=CC=2)C)CCC1 RJBNASUMBSVTNZ-UHFFFAOYSA-N 0.000 claims 1
- AXBIWDSPWVFALW-UHFFFAOYSA-N [6-(4-methoxy-3-propan-2-yloxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C1=NN(C(=O)C2=C(N=C(S2)C=2C=NC=CC=2)C)CCC1 AXBIWDSPWVFALW-UHFFFAOYSA-N 0.000 claims 1
- SWRDSZZAEUQOEK-UHFFFAOYSA-N [6-(4-methoxy-3-propan-2-yloxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-methyl-2-thiophen-2-yl-1,3-thiazol-5-yl)methanone Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C1=NN(C(=O)C2=C(N=C(S2)C=2SC=CC=2)C)CCC1 SWRDSZZAEUQOEK-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 claims 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 208000028462 aluminosis Diseases 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 208000010123 anthracosis Diseases 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims 1
- 150000007514 bases Chemical class 0.000 claims 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000005681 cholinergic urticaria Diseases 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 229960004022 clotrimazole Drugs 0.000 claims 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 1
- 206010009869 cold urticaria Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 229960003913 econazole Drugs 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000009320 ethmoid sinusitis Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 210000003746 feather Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000006916 frontal sinusitis Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 201000010056 fungal meningitis Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims 1
- 206010021247 idiopathic urticaria Diseases 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 201000008836 maxillary sinusitis Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002509 miconazole Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000007892 occupational asthma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 208000018916 plastic bronchitis Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- 229940041153 polymyxins Drugs 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000028172 protozoa infectious disease Diseases 0.000 claims 1
- 238000005932 reductive alkylation reaction Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000006476 shipyard eye Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 208000004003 siderosis Diseases 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 201000006923 sphenoid sinusitis Diseases 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 150000003536 tetrazoles Chemical group 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10227269A DE10227269A1 (de) | 2002-06-19 | 2002-06-19 | Thiazolderivate |
| DE10227269.7 | 2002-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005101202A true RU2005101202A (ru) | 2005-07-10 |
Family
ID=29719229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005101202/04A RU2005101202A (ru) | 2002-06-19 | 2003-04-28 | Производные тиазола в качестве ингибиторов фосфодиэстераза iv |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7790723B2 (enExample) |
| EP (1) | EP1513837B1 (enExample) |
| JP (1) | JP4555076B2 (enExample) |
| AR (1) | AR039695A1 (enExample) |
| AT (1) | ATE338041T1 (enExample) |
| AU (1) | AU2003232215B2 (enExample) |
| BR (1) | BR0311879A (enExample) |
| CA (1) | CA2489902C (enExample) |
| DE (2) | DE10227269A1 (enExample) |
| ES (1) | ES2271642T3 (enExample) |
| MX (1) | MXPA04012428A (enExample) |
| PL (1) | PL372123A1 (enExample) |
| RU (1) | RU2005101202A (enExample) |
| WO (1) | WO2004000839A1 (enExample) |
| ZA (1) | ZA200500484B (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10227269A1 (de) * | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| AU2005247906B2 (en) | 2004-05-18 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7910708B2 (en) | 2005-10-21 | 2011-03-22 | Novartis Ag | Anti-IL13 human antibodies |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| ATE549337T1 (de) | 2006-04-21 | 2012-03-15 | Novartis Ag | Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| KR20090075714A (ko) | 2006-10-30 | 2009-07-08 | 노파르티스 아게 | 소염제로서의 헤테로시클릭 화합물 |
| RS51644B (sr) | 2007-01-10 | 2011-10-31 | Irm Llc. | Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze |
| KR20100005730A (ko) | 2007-05-07 | 2010-01-15 | 노파르티스 아게 | 유기 화합물 |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| EP2231642B1 (en) | 2008-01-11 | 2013-10-23 | Novartis AG | Pyrimidines as kinase inhibitors |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| WO2010009243A1 (en) | 2008-07-15 | 2010-01-21 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| EA021019B1 (ru) | 2009-06-18 | 2015-03-31 | Концерт Фармасьютикалс, Инк. | Дейтерированные производные изоиндолин-1,3-диона |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| MY162604A (en) | 2009-08-17 | 2017-06-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物 |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| AU2012220572A1 (en) | 2011-02-25 | 2013-08-29 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
| EA021233B1 (ru) * | 2012-03-14 | 2015-05-29 | Ооо "Фармацевтическая Компания "Славянская Аптека" | Фармацевтический состав, обладающий сосудосуживающим, антиконгестивным, противовоспалительным действием (варианты) |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| CN110507654A (zh) | 2012-04-03 | 2019-11-29 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| TW201348214A (zh) * | 2012-04-26 | 2013-12-01 | Toyama Chemical Co Ltd | 氘化含氮雜環羧醯胺衍生物 |
| WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
| US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| JP6474963B2 (ja) * | 2014-03-04 | 2019-02-27 | 持田製薬株式会社 | 洗浄用組成物 |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| PL3134395T3 (pl) | 2014-04-24 | 2018-07-31 | Novartis Ag | Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu |
| US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| CA3017740A1 (en) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
| US10782276B2 (en) | 2018-06-14 | 2020-09-22 | Manufacturing Resources International, Inc. | System and method for detecting gas recirculation or airway occlusion |
| EA202190248A1 (ru) | 2018-07-11 | 2021-06-16 | Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. | Димерные иммуномодулирующие соединения против механизмов на основе цереблона |
| EP3980121A1 (en) | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| PH12022550468A1 (en) | 2019-08-28 | 2023-03-06 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533975A1 (de) * | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
| DE19632549A1 (de) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE10227269A1 (de) * | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
-
2002
- 2002-06-19 DE DE10227269A patent/DE10227269A1/de not_active Withdrawn
-
2003
- 2003-04-28 RU RU2005101202/04A patent/RU2005101202A/ru not_active Application Discontinuation
- 2003-04-28 WO PCT/EP2003/004434 patent/WO2004000839A1/de not_active Ceased
- 2003-04-28 CA CA2489902A patent/CA2489902C/en not_active Expired - Fee Related
- 2003-04-28 US US10/518,503 patent/US7790723B2/en not_active Expired - Fee Related
- 2003-04-28 MX MXPA04012428A patent/MXPA04012428A/es unknown
- 2003-04-28 JP JP2004514623A patent/JP4555076B2/ja not_active Expired - Fee Related
- 2003-04-28 DE DE50304867T patent/DE50304867D1/de not_active Expired - Lifetime
- 2003-04-28 ES ES03760583T patent/ES2271642T3/es not_active Expired - Lifetime
- 2003-04-28 AT AT03760583T patent/ATE338041T1/de not_active IP Right Cessation
- 2003-04-28 BR BR0311879-7A patent/BR0311879A/pt not_active Application Discontinuation
- 2003-04-28 PL PL03372123A patent/PL372123A1/xx unknown
- 2003-04-28 AU AU2003232215A patent/AU2003232215B2/en not_active Ceased
- 2003-04-28 EP EP03760583A patent/EP1513837B1/de not_active Expired - Lifetime
- 2003-06-18 AR ARP030102149A patent/AR039695A1/es not_active Application Discontinuation
-
2005
- 2005-01-18 ZA ZA200500484A patent/ZA200500484B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE338041T1 (de) | 2006-09-15 |
| CA2489902C (en) | 2011-11-22 |
| PL372123A1 (en) | 2005-07-11 |
| ES2271642T3 (es) | 2007-04-16 |
| CA2489902A1 (en) | 2003-12-31 |
| EP1513837A1 (de) | 2005-03-16 |
| ZA200500484B (en) | 2006-04-26 |
| DE50304867D1 (en) | 2006-10-12 |
| DE10227269A1 (de) | 2004-01-08 |
| MXPA04012428A (es) | 2005-04-19 |
| BR0311879A (pt) | 2005-03-15 |
| AU2003232215A1 (en) | 2004-01-06 |
| AR039695A1 (es) | 2005-03-09 |
| WO2004000839A1 (de) | 2003-12-31 |
| JP4555076B2 (ja) | 2010-09-29 |
| AU2003232215B2 (en) | 2009-04-30 |
| JP2005530825A (ja) | 2005-10-13 |
| US7790723B2 (en) | 2010-09-07 |
| US20050222160A1 (en) | 2005-10-06 |
| EP1513837B1 (de) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200304894B (en) | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes. | |
| CA2489902A1 (en) | Thiazole derivatives as phosphodiesterase iv inhibitors | |
| ES2248231T3 (es) | Derivados de eteres utiles como inhibidores de las isozimas pde4. | |
| CA2475712A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| AU2003240259B2 (en) | Aryloximes | |
| RU2004122924A (ru) | Пирролпиримидины в качестве ингибиторов фосфодиэстеразы v11 | |
| ES2223772T3 (es) | Pirimidincarboxamidas utiles como inhibidores de las isozimas pde4. | |
| ES2238415T3 (es) | Derivados de nicotinamida benzocondensada-heterociclilo utiles como inhibidores selectivos de isozimas pde4. | |
| ES2239203T3 (es) | Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4. | |
| ZA200305769B (en) | Thiazolyl-, oxazolyl-, pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes. | |
| US20020111495A1 (en) | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | |
| RU2004139032A (ru) | Производные пиридазина | |
| RU2004117171A (ru) | Гидразоно-малонитрилы | |
| CN101479258A (zh) | 作为磷脂酰肌醇3-激酶抑制剂的噻唑基脲类衍生物 | |
| ES2286650T3 (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| MXPA06000928A (es) | Derivados de nicotinamida utiles como inhibidores de fosfodiesterasas 4. | |
| US7132435B2 (en) | Compounds | |
| CA2536383A1 (en) | Nicotinamide compounds useful as pde4 inhibitors | |
| WO2005010001A1 (en) | Nicotinamide derivatives useful as pdea4 inhibitors | |
| TH72658A (th) | สารประกอบ | |
| ZA200405803B (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| TH62552A (th) | การใช้ประโยชน์ไพริมิดินคาร์บอกซาไมด์ในฐานะเป็นตัวยับยั้ง pde4 ไอโซไซม์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060707 |